FDA Clears Three-In-One Drug for High Blood Pressure
A three-in-one combination drug is available for the treatment of hypertension in patients who do not respond to dual medical treatment. Daiichi Sankyo Inc. said Tribenzor (olmesartan medoxomil, amlodipine, hydrochlorothiazide) is taken once-daily by patients who are not adequately controlled on any two of the following antihypertensive drug classes: angiotensin receptor blockers, calcium channel blockers and diuretics. Tribenzor is not indicated for initial therapy.
A fixed-dose combination treatment, Tribenzor simplifies dosing regimens, reduces pill burden and has the potential to lower copays for patients that require three medications to keep blood pressure within recommended levels. After eight weeks of treatment, Tribenzor produced highly statistically significantly greater reductions in both systolic and diastolic blood pressures compared to each of the three dual combination therapies.
The most common adverse reactions (incidence greater than or equal to 2 percent) seen in clinical trials for Tribenzor were dizziness, peripheral edema, headache, fatigue, nasopharyngitis, muscle spasms, nausea, upper respiratory tract infection, diarrhea, urinary tract infection, and joint swelling.
For more information: www.tribenzor.com